Table 1.
Independent variables’ levels and response constraint used in the Box-Behnken design for the optimization of ALS-MP nanoconjugates.
Table 2.
Variables levels and observed response (particle size) for ALS-MP nanoconjugates experimental runs formulated according to Box-Behnken design generated.
Table 3.
Model fit statistics for the particle size of ALS-MP nanoconjugates.
Fig 1.
Diagnostic plots for particle size of ALS-MP nanoconjugates: (A) Box-Cox for power transforms, (B) externally studentized residuals vs. predicted particle size, (C) ex-ternally studentized residuals vs. run number, and (D) predicted vs. actual particle size.
Abbreviations: ALS, Alendronate sodium; MP, Mastoparan peptide.
Fig 2.
Response 3D-plots (A-C) and contour 2D-plots (D-F) for the influence of ALS:MP molar ratio (X1), incubation time (X2), and sonication (X3) on the particle size of ALS-MP nanoconjugates.
Fig 3.
The in vitro release pattern of drug from optimized ALS-MP and ALS-raw.
Fig 4.
Comparative cytotoxicity of various samples in terms of IC50.
*Significantly different from Staurosporine p<0.05, #significantly different from MP p<0.05, $signifi-cantly different from ALS p<0.05.
Fig 5.
Effect of various formulations on cell cycle.
*Significantly different from control p<0.05, #significantly different from MP p<0.05, $significantly different from ALS-Raw p<0.05.
Fig 6.
Determination of cellular mortality after Annexin V staining by flow cytometry.
*Significantly different from control p<0.05, #significantly different from MP p<0.05, $sig-nificantly different from ALS-Raw p<0.05.
Fig 7.
Comparative effects of ALS-MP on Caspase 3.
*Significantly different from control p<0.05, #significantly different from MP p<0.05.